Developing new ways to treat nerve damage and chronic pain using the body’s own proteins
Sinfonia Biotherapeutics uses the body’s reparative proteins to develop effective treatments for nerve damage and chronic pain. The therapies are developed for the treatment of diseases such as sciatica, diabetic pain, Parkinson’s disease, epilepsy and hearing loss.
Today, approximately 100 million people suffer from various diseases that affect the nervous system. In many cases, the nerve damage results in so-called chronic neuropathic pain. Sinfonia Biotherapeutics takes advantage of the body’s own proteins to repair damage to the nervous system and relieve pain.
“We are currently conducting the necessary clinical studies to show that one of our products, SB0101, works both to treat the pain and to repair the damaged nerves”, says Lars Wahlberg, CEO and CMO at Sinfonia Biotherapeutics.
Kick-starting the body’s repair system
Some of our proteins have the ability to switch on the self-repairing functions of the nervous system. One of these is neublastin, SB0101, which Sinfonia is developing for the treatment of chronic sciatica and a range of other nerve injuries affecting the peripheral nervous system.
“SB0101 is given via an injection into the arm and activates the body’s own functions to repair damage to the nervous system. Here we have shown very positive results with, among other things, clinical “proof of concept” in patients with severe chronic sciatica. It is an indication for which there is currently no approved painkiller. Our hope is to be the first company to get a treatment for chronic sciatica pain approved.”
The same methodology can also be used to repair damage to the brain caused by conditions such as Parkinson’s, epilepsy and frontal lobe dementia. Although for these conditions, an injection in the arm is not enough because the brain is very effectively protected by the so-called blood-brain barrier. Instead, Sinfonia is developing a platform to – in simple terms – to place a small pharmaceutical “factory” in the damaged area of the brain.
The factory consists of an implant with living cells that produce the necessary signaling proteins. When they leave the implant, it triggers a repair of the nerves directly in place.
“The technique of doing these brain surgeries is already well established in most neurosurgery centers in the world. With the help of the so-called stereotactic technique, we can place our implants in the desired area of the brain with very good precision.”
These small pharmaceutical factories can be placed in an area where an epileptic seizure occurs, for example, or among nerve cells damaged by Parkinson’s or dementia.
Sinfonia Biotherapeutics’ focus on Parkinson’s has resulted in the company receiving a research grant from the Michael J. Fox Foundation for Parkinson’s Research (MJFF).
Sinfonia’s solution combines advances in advanced therapy drugs (ATMPs) with medtech innovations. Several additional applications are planned, including an implant that can be placed in the inner ear to treat age-related hearing loss and hearing damage due to loud sound or noise.
“Our main focus is to use the signaling proteins to be able to create new treatments for diseases where there is currently a lack of effective treatments.”
Today, Sinfonia Biotherapeutics is based in Flemingsberg and outside Boston, in the US. On Campus Flemingsberg the company has several research collaborations with well-known research groups from Karolinska University Hospital and Karolinska Institutet.
“We hope to become part of the excellent research that is being done into ATPMs, which offers world-leading knowledge and the opportunity to develop new therapies all the way from idea to clinical trials,” Johan Lundkvist, vice president of Sinfonia Biotherapeutics.
Now Open: Flemingsberg Science Award STARTUP 2026
Do you have a business idea that can make a difference, locally or globally? Flemingsberg Science Award STARTUP is the competition for those who want to challenge their idea, gain valuable feedback from experienced experts, and take the first step toward building something real.
Campus Flemingsberg continues to grow – more students and strong collaboration in focus
Campus Flemingsberg remains one of Sweden’s most dynamic knowledge environments. Over the past year, the number of students has increased from 24,000 to approximately 27,000. The trend is clear: the campus’s broad academic profile continues to attract a growing number of students.
Limitless Potential: Winner of the Flemingsberg Science Award 2025
Young people in disadvantaged areas often face mental health challenges and a lack of support, which can lead to isolation and destructive choices. Limitless Potential, winner of the Flemingsberg Science Award IDEA 2025, has created a safe space where creativity and social entrepreneurship come together to support youth.
Alfa Laval strengthens Flemingsberg – establishes itself in a growing city of the future
In May 2025, Alfa Laval moved into its new office and innovation center, spanning approximately 20,000 square meters, together with around 700 employees. At the same time, the restaurant K-märkt opened, further expanding the range of services available in Flemingsberg. The Royal Swedish Opera and Dramaten, Alfa Laval, Restaurant Billmans, and K-märkt all represent important pieces of the puzzle in the development of Flemingsberg.
En nationell resurs för morgondagens behandlingar – nu är Karolinska ATMP Centrum invigt
Med ett tydligt budskap om framtidstro och ett kraftfullt samarbete invigdes Karolinska ATMP Centrum i Flemingsberg i slutet av augusti. Centret är ett samarbete mellan Karolinska Institutet och Karolinska Universitetssjukhuset, och kommer fungera som en nationell resurs för tillverkning av avancerade terapier (ATMP), där forskning, kliniska prövningar och behandlingar smidigt samverkar för att leverera banbrytande terapier till patienter.
